-------------------------------------------------------------------------------- | NeuroSearch to present at Cowen's 27th Annual US Health Care Conference in | | Boston | -------------------------------------------------------------------------------- | NeuroSearch (NEUR) will present at Cowen's 27th Annual Health Care | | Conference to be held from Monday 12 to Thursday 15 March at The Boston | | Marriott Copley Place Hotel, 110 Huntington Avenue, Boston, USA. | | The presentation will be held by Flemming Pedersen, CEO, and is scheduled | | for | | Tuesday 13 March at 3:15 - 3:50 pm | | The presentation will be followed by a breakout session at 4:00 - 4:35 pm. | | A PowerPoint version of the presentation will be accessible on our website | | www.neurosearch.com just prior to the presentation at the conference. | -------------------------------------------------------------------------------- | Contact: | Hanne Leth Hillman, Vice President, Director of Investor | | | Relations and Corporate Communications | | | Phone: +45 4460 8212 or +45 4017 5103 | -------------------------------------------------------------------------------- | NeuroSearch is a Scandinavian biopharmaceutical company listed on the | | Copenhagen Stock Exchange (NEUR). Our core business covers the development | | of novel drugs, based on a broad and well-established drug discovery | | platform focusing on ion channels and transporters. A substantial part of | | the company's activities are partner financed through a broad alliance with | | GlaxoSmithKline (GSK) and collaborations with among others Abbott and | | Astellas. Nine drug programmes are in clinical development: ACR16 for the | | treatment of Huntington's disease (under preparation for Phase III), | | tesofensine for the treatment of obesity/type 2 diabetes (Phase II), NS2359 | | for the treatment of depression (Phase II) and ADHD (Phase II) in | | partnership with GSK, NS1209 for the treatment of epilepsy and pain (Phase | | II), ABT-894 for the treatment of ADHD (Phase II) and neuropathic pain | | (Phase I) in partnership with Abbott, ACR16 for the treatment of | | schizophrenia (Phase I) in partnership with Astellas, and ACR325 for the | | treatment of psychoses and bipolar disorder (Phase I). In addition, | | NeuroSearch has a broad portfolio of preclinical drug candidates and has | | equity interests in several biotech companies. | --------------------------------------------------------------------------------
NeuroSearch to present at Cowen's 27th Annual US Health Care Conference in Boston
| Source: NTG Nordic Transport Group A/S